Assessment of pharmacotherapy for negative symptoms of schizophrenia

Current Psychiatry Reports

Volumn 12, Issue 6, 2010, Pages 563-571

  Hanson, Elizabeth ^a   Healey, Kristin ^a   Wolf, Daniel ^a   Kohler, Christian ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Negative symptoms; NMDA agonist; Pharmacotherapy; Schizophrenia; Treatment

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ASENAPINE; ATOMOXETINE; BUSPIRONE; CITALOPRAM; CYCLOSERINE; DONEPEZIL; FANAPT; GALANTAMINE; HALOPERIDOL; ILOPERIDONE; LAMOTRIGINE; MEMANTINE; MINOCYCLINE; MIRTAZAPINE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PLACEBO; PRASTERONE; RALOXIFENE; REBOXETINE; RISPERIDONE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; BODY WEIGHT DISORDER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG RESEARCH; HUMAN; NEGATIVE SYNDROME; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 78649907123     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0148-0     Document Type: Review

References (50)

1. P Liddle 1987 The symptoms of chronic schizophrenia: a reexamination of the positive-negative dichotomy Br J Psychiatry 151 145 151 1:STN:280: DyaL1c%2FnvVKluw%3D%3D 10.1192/bjp.151.2.145 3690102
2. P Milev BC Ho S Arndt NC Andreasen 2005 Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up Am J Psychiatry 162 495 506 10.1176/appi.ajp.162.3.495 15741466 (Pubitemid 40343916)
3. RW Buchanan M Davis D Goff, et al. 2005 A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia Schizophr Bull 31 5 19 10.1093/schbul/sbi020 15888422 (Pubitemid 41214353)
4. Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
5. SR Kay A Fiszbein LA Opler 1987 The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 261 276 1:STN:280: DyaL2s3ptF2huw%3D%3D 3616518
6. JE Overall DR Gorham 1962 The Brief Psychiatric Rating Scale Psychol Rep 10 799 812 10.2466/PR0.10.3.799-812
7. RW Kirkpatrick PD Buchanan LD McKenney, et al. 1989 The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia Psychiatry Res 30 119 123 1:STN:280:DyaK3c7jvFentg%3D%3D 10.1016/0165-1781(89)90153-4 2616682 (Pubitemid 20005923)
8. L Alphs A Summerfelt H Lan RJ Muller 1989 The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia Psychopharmacol Bull 25 159 163 1:STN:280:DyaK3c%2FpvFKrsw%3D%3D 2602512
9. G Juckel F Schlagenhauf M Koslowski, et al. 2006 Dysfunction of ventral striatal reward prediction in schizophrenia Neuroimage 29 409 416 10.1016/j.neuroimage.2005.07.051 16139525 (Pubitemid 43063297)
10. RE Gur J Loughead CG Kohler, et al. 2007 Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia Arch Gen Psychiatry 64 1356 1366 10.1001/archpsyc.64.12.1356 18056543 (Pubitemid 350223553)
11. AA Sepehry S Potvin R Élie E Stip 2007 SSRI add-on therapy for the negative symptoms of schizophrenia: a meta-analysis J Clin Psychiatry 68 604 610 1:CAS:528:DC%2BD2sXlsF2ksr4%3D 10.4088/JCP.v68n0417 17474817
12. R Zoccali MR Muscatello A Bruno, et al. 2007 The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study Schizophr Res 93 109 116 1:STN:280:DC%2BD2szivFOktg%3D%3D 10.1016/j.schres.2007.02.009 17383857 (Pubitemid 46817934)
13. SG Potkin RE Litman R Torres CD Wolfgang 2008 Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies J Clin Psychopharmacol 28 S4 S11 1:CAS:528:DC%2BD1cXjtVKgtL0%3D 10.1097/JCP.0b013e3181692787 18334911 (Pubitemid 351397671)
14. A Thompson C Lavedan S Volpi 2010 Absence of weight gain association with the HTRC-759C/T polymorphism in patients with schizophrenia treated with iloperidone Psychiatr Res 165 271 273 10.1016/j.psychres.2009.03.020
15. S Volpi SG Potkin AK Malhotra, et al. 2009 Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia J Clin Psychiatry 70 801 809 1:CAS:528:DC%2BD1MXhsFentbnL 10.4088/JCP.08m04391 19573479
16. R Emsley PD Doelder J Schoemaker D Naber 2008 Long-term safety of asenapine in patients with schizophrenia Schizophr Res 98 Suppl 1 48
17. J Weber PL McCormack 2009 Asenapine CNS Drugs 23 781 792 1:CAS:528:DC%2BD1MXht1KiurjF 10.2165/11200860-000000000-00000 19689168
18. R Zoccali MR Muscatello C Cedro, et al. 2004 The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study Int Clin Psychopharmacol 19 71 76 10.1097/00004850-200403000-00003 15076014 (Pubitemid 38324586)
19. M Berk C Ichim S Brook 2001 Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study Int Clin Psychopharmacol 16 87 92 1:STN:280:DC%2BD3M7nsVOnsw%3D%3D 10.1097/00004850-200103000-00003 11236073 (Pubitemid 32171833)
20. SH Abbasi H Behpournia A Ghoreshi, et al. 2010 The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial Schizophr Res 116 101 106 10.1016/j.schres.2009.11.008 19959338
21. G Joffe V Terevnikov M Joffe, et al. 2009 Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial Schizophr Res 108 245 251 10.1016/j.schres.2008.12.002 19144501
22. M Berk CS Gama S Sundram, et al. 2009 Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomized, placebo-controlled clinical trial Hum Psychopharmacol Clin Exp 24 233 238 1:CAS:528:DC%2BD1MXlsVars7o%3D 10.1002/hup.1017
23. M Berk C Ichim S Brook 2001 Efficacy of mirtazapine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study Int Clin Psychopharmacol 16 87 92 1:STN:280:DC%2BD3M7nsVOnsw%3D%3D 10.1097/00004850-200103000-00003 11236073 (Pubitemid 32171833)
24. S Zisook JW Kasckow S Golshan, et al. 2009 Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial J Clin Psychiatry 70 562 571 1:CAS:528:DC%2BD1MXhsFaqtbbJ 10.4088/JCP.08m04261 19192468
25. M Poyurovsky S Faragian C Fuchs, et al. 2009 Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study Isr J Psychiatry Relat Sci 46 213 220 20039523
26. T Sumiyoshi S Park K Jayathilake, et al. 2007 Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr Res 95 158 168 10.1016/j.schres.2007.06.008 17628435 (Pubitemid 47313647)
27. D Piskulic JS Olver P Maruff TR Norman 2009 Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist Hum Psychopharmacol 24 437 446 1:CAS:528:DC%2BD1MXhtFGhtrjN 10.1002/hup.1046 19637398
28. R Freedman M Hall LE Adler S Leonard 1995 Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol Psychiatry 38 22 33 1:CAS:528:DyaK2MXnt12mu7c%3D 10.1016/0006-3223(94) 00252-X 7548469
29. CR Breese MJ Lee CE Adams, et al. 2000 Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia Neuropsychopharmacology 23 351 364 1:CAS:528:DC%2BD3cXmtlGls7k%3D 10.1016/S0893-133X(00)00121-4 10989262
30. S Akhondzadeh M Gerami M Noroozian, et al. 2008 A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 32 1810 1815 1:CAS:528:DC%2BD1cXhsVerurnE 10.1016/j.pnpbp.2008.08.001 18727948
31. RR Conley DL Boggs DL Kelly, et al. 2009 The effects of galantamine on psychopathology in chronic stable schizophrenia Clin Neuropharmacol 32 69 74 1:CAS:528:DC%2BD1MXlt1Giu78%3D 10.1097/WNF.0b013e31816f2795 18978489
32. JA Lieberman K Papadakis J Csernansky, et al. 2009 A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology 34 1322 1329 1:CAS:528: DC%2BD1MXjtFentL4%3D 10.1038/npp.2008.200 19005465
33. D De Lucena BS Fernandes M Berk, et al. 2009 Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine J Clin Psychiatry 70 1416 1423 10.4088/JCP.08m04935gry 19906345
34. KA Sacco C Creeden EL Reutenauer, et al. 2009 Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia Schizophr Res 107 332 333 10.1016/j.schres.2008.09.026 18995989
35. DL Kelly RW Buchanan DL Boggs, et al. 2009 A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia J Clin Psychiatry 70 518 525 1:CAS:528:DC%2BD1MXhsFaqtbbN 10.4088/JCP.08m04358 19358788
36. O Freudenreich DC Henderson EA Macklin, et al. 2009 Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial J Clin Psychiatry 70 1674 1680 1:CAS:528:DC%2BC3cXht1antbk%3D 10.4088/JCP.08m04683 19689921
37. DC Turner I Clark E Pomarol-Clotet, et al. 2004 Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia Neuropsychopharmacology 29 1363 1373 1:CAS:528:DC%2BD2cXkvFWltLs%3D 10.1038/sj.npp.1300457 15085092 (Pubitemid 38780659)
38. JH Krystal LP Karper JP Seibyl, et al. 1994 Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 199 214 1:CAS:528:DyaK2cXkslemtrY%3D 8122957
39. D Quartermain J Mower MF Rafferty, et al. 1994 Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention Eur J Pharmacol 257 7 12 1:CAS:528:DyaK2cXktVWltb0%3D 10.1016/0014-2999(94)90687-4 8082709 (Pubitemid 24178543)
40. DC Goff C Cather JD Gottlieb, et al. 2008 Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study Schizophr Res 106 320 327 10.1016/j.schres.2008.08.012 18799288
41. HY Lane CH Lin YJ Huang, et al. 2010 A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia Int J Neuropsychopharmacol 13 451 460 1:CAS:528:DC%2BC3cXkvFeku7Y%3D 10.1017/S1461145709990939 19887019 Sarcosine represents an intermediate byproduct in glycine metabolism. Blocking the glycine transporter increases glycine concentrations in the brain and enhances NMDA receptor functioning. In 60 individuals with chronic schizophrenia in this study, sarcosine improved negative symptoms and quality of life as compared with serine and placebo
42. CE Marx RSE Keefe RW Buchanan, et al. 2009 Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia Neuropsychopharmacology 34 1885 1903 1:CAS:528: DC%2BD1MXnsFSju7k%3D 10.1038/npp.2009.26 19339966
43. J Kulkarni C Gurvich SJ Lee, et al. 2010 Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia Psychoneuroendocrinology 35 1142 1147 1:CAS:528:DC%2BC3cXhtVaqu7zK 10.1016/j.psyneuen.2010.01.014 20171784
44. Y Levkovitz S Mendlovich S Riwkes, et al. 2010 A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia J Clin Psychiatry 71 138 149 1:CAS:528: DC%2BC3cXktVSgt7w%3D 10.4088/JCP.08m04666yel 19895780 Minocycline, a second-generation tetracycline, has been found to exert neuroprotective effects in animal studies via effects on the NMDA receptor complex. In this study, 70 individuals with early-phase schizophrenia were randomly assigned to minocycline versus placebo for 5 months. Minocycline was well-tolerated and improved negative symptoms and executive functioning
45. ID Glick J Bosch DE Casey 2009 A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive J Clin Psychopharmacol 29 267 271 1:CAS:528:DC%2BD1MXlvV2htrw%3D 10.1097/JCP.0b013e3181a443d0 19440081
46. PD McGorry AR Yung LJ Phillips, et al. 2002 Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms Arch Gen Psychiatry 59 921 928 10.1001/archpsyc.59.10.921 12365879
47. TH McGlashan RB Zipursky D Perkins, et al. 2006 Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis Am J Psychiatry 163 790 799 10.1176/appi.ajp.163.5.790 16648318 (Pubitemid 44464525)
48. MP Freeman JR Hibbeln KL Wisner, et al. 2006 Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry J Clin Psychiatry 67 1954 1967 1:CAS:528:DC%2BD2sXhtFykurs%3D 10.4088/JCP.v67n1217 17194275
49. CB Joy R Mumby-Croft LA Joy 2006 Polyunsaturated fatty acid supplementation for schizophrenia Cochrane Database Syst Rev 3 CD001257 1:STN:280:DC%2BD28vntFWjtw%3D%3D 16855961
50. GP Amminger MR Schafer K Papageorgiou, et al. 2010 Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders Arch Gen Psychiatry 67 146 154 1:CAS:528:DC%2BC3cXis1aisbo%3D 10.1001/archgenpsychiatry.2009.192 20124114 Conversion to psychosis in young individuals at clinical risk of schizophrenia represents a major treatment goal. Dysfunctional fatty acid metabolism may contribute to the etiology of schizophrenia. In 81 young individuals with subthreshold symptoms of psychosis in this study, polyunsaturated fatty acid augmentation for 12 weeks was associated with decreased risk of progression to psychosis over 1 year